Navigation Links
RRD Selected as Development Partner for NIH Therapeutics for Rare and Neglected Diseases Program
Date:1/24/2011

ROCKVILLE, Md., Jan. 24, 2011 /PRNewswire/ -- RRD International, a strategy-driven biotech and pharmaceutical product development company, announced today that it has entered into a partnership with the National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program as a regulatory support and development partner.

The RRD and TRND partnership will focus on two rare disease drug development projects: Hereditary Inclusion Body Myopathy (HIBM), a rare adult-onset neuromuscular disorder and Niemann Pick type C1 Disease (NPC1), a rare neurodegenerative genetic disease.  

"We look forward to combining the product development strengths of RRD with the resources of the NIH TRND program to develop important new treatments for these rare diseases," said Charles (Chuck) Finn, Ph.D., President, CEO, and Co-Founder of RRD International.

As a new congressionally mandated program, TRND is designed to advance preclinical and early clinical development of new drugs for rare and neglected diseases. The program also drives forward adoption of new technologies and treatment paradigms which improve product development efficiency for these diseases.  TRND has formed numerous collaborations with researchers from academia and industry to work on specific rare or neglected diseases.  

"TRND has established partnerships with companies and researchers to identify the most promising molecules that may result in new treatments for rare and neglected diseases," said Christopher P. Austin, M.D., director of the NIH TRND effort. "It is important to note that drug development is not a trivial process and the failure rate for any molecule or compound is high."

The program aims to speed development of new drugs that might otherwise be ignored by industry because they are too early in the development process where the failure rates are high or would not be sufficiently profitable. To make a potential compound attractive to private partners in order to get a treatment to patients, TRND advances a potential compound through the drug development process to the point where it can be tested in people. TRND provides all aspects of preclinical development needed to turn promising compounds into potential medicines ready for clinical evaluation.

"This partnership is another validation of our development philosophy and the success we've achieved with other products," said Scott Tarrant, Chief Business Officer at RRD International. "Work on these rare diseases will demonstrate the flexibility of our asset-centric model and how RRD efficiently drives development while mitigating cost and risk factors which, historically, have served as barriers to new therapies for rare and neglected diseases."

The TRND program will collaborate with academic organizations, foundations, biotechs, and pharmaceutical companies to develop clinical candidate drugs that can be adopted by biopharma for completion of clinical development and FDA approval.  In addition to individual drug development projects, TRND is developing technologies and paradigms to reduce the very high risks and cost of drug development. The ultimate goal is to "de-risk" rare and neglected disease drug development by accomplishing lead optimization through an FDA Investigational New Drug (IND) application and, when needed, proof-of-concept in human studies.

About RRD International

Founded in 2002, RRD is a strategy-driven product development company.  The Company's development model enables rapid proof-of-concept for biotech and pharmaceutical clients to accelerate value inflection points; reduce costs; and mitigate development as well as execution risk.  RRD offers two distinct types of client engagements:  TacDev® and DevCo®.  The TacDev® model adds development bandwidth and expertise for defined products in companies with minimal infrastructure.  The DevCo® model creates external product development companies where investment is in asset optimization rather than traditional infrastructure.  For more information visit www.rrdintl.com.  RRD International: Accelerating the Right Development; Creating Lasting Value.

About TRND

The National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program, http://trnd.nih.gov is a congressionally mandated program to encourage and speed the development of new drugs for rare and neglected diseases.  This unique program creates a drug development pipeline within the NIH and is specifically intended to stimulate research collaborations with academic scientists, non-profit organizations, and pharmaceutical and biotechnology companies working on rare and neglected illnesses.  The TRND program provides an opportunity to partner with, and gain access to, drug development scientific capabilities, expertise, and resources in a collaborative environment with the goal of moving promising therapeutics into clinical testing.


'/>"/>
SOURCE RRD International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
2. CSA Medical Selected to Present at Mid-Atlantic Bio Conference
3. PMC BioTec Selected as a GoingGreen Silicon Valley 100 Winner
4. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
5. Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility
6. Ion Torrent Selected as World Economic Forum Technology Pioneer
7. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
8. Genedata Phylosopher Selected for ERA-NET sncRNA Project
9. NeoStem Selected to Present at American Society for Apheresis
10. DNA Genoteks Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project
11. OrthoAccel Technologies, Inc. Selected to Pitch at the 2010 WBTshowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... , ... LABS, Inc. (LABS) announced in December 2016 that two new ... Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific for IgM and IgG ... blood donors under an Investigational New Drug (IND) study protocol. , Now, as ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... EMEA and North America this May on the following dates: ... Donald H. Taylor, Chairman of the Learning and Performance Institute will be the ...
(Date:4/26/2017)... April 26, 2017  Genisphere LLC, provider of ... signed a collaborative and sponsored research agreement with ... Muro . The overall goal of the partnership ... various 3DNA designs and formulations after in ... of the vasculature as well as inflammatory responses, ...
(Date:4/25/2017)... Oakland, California (PRWEB) , ... April 25, 2017 ... ... Artificial Intelligence (AI), leading supplier of Common Lisp (CL) development tools, and market ... 10.1 , which includes key performance enhancements now available within the most effective ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):